Alpha 2.0
Login Register
» Articles » PMID: 24970841

The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2014 Jun 28
PMID 24970841
Citations 51
Authors
Antoni Ribas
Paul C Tumeh
Affiliations
Soon will be listed here.
Abstract

It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1 blockade will be the initial decision point to select the treatment of patients with any cancer type.

Citing Articles

HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.

Amrane K, Le Meur C, Besse B, Hemon P, Le Noach P, Pradier O Front Immunol. 2024; 14:1285895.

PMID: 38299143 PMC: 10827890. DOI: 10.3389/fimmu.2023.1285895.

Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India.

Ganie F, Mehfooz N, Siraj F, Khan U, Mantoo S, Dhar A Cureus. 2023; 15(2):e35056.

PMID: 36942175 PMC: 10024510. DOI: 10.7759/cureus.35056.

PDJ amplicon in triple negative breast cancer.

Roesler A, Malasi S, Koslosky L, Hartmayer P, Naab T, Carter J Sci Rep. 2023; 13(1):618.

PMID: 36635351 PMC: 9837184. DOI: 10.1038/s41598-023-27887-8.

Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience.

Park S, Lee H, Lee S, Hong R In Vivo. 2023; 37(1):233-241.

PMID: 36593005 PMC: 9843772. DOI: 10.21873/invivo.13072.

A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.

Liu Z, Qi T, Li X, Yao Y, Othmane B, Chen J Front Immunol. 2022; 12:791924.

PMID: 34975891 PMC: 8718409. DOI: 10.3389/fimmu.2021.791924.

References
1.
Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View
2.
Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View
3.
Taube J, Klein A, Brahmer J, Xu H, Pan X, Kim J . Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20(19):5064-74. PMC: 4185001. DOI: 10.1158/1078-0432.CCR-13-3271. View
4.
Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View
5.
Robins H, Ericson N, Guenthoer J, OBriant K, Tewari M, Drescher C . Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med. 2013; 5(214):214ra169. PMC: 4026017. DOI: 10.1126/scitranslmed.3007247. View